MicroRNA-940 as a Potential Serum Biomarker for Prostate Cancer.
PSA
circulating miRNA
miR-940
prostate cancer
serum
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
11
2020
accepted:
23
02
2021
entrez:
5
4
2021
pubmed:
6
4
2021
medline:
6
4
2021
Statut:
epublish
Résumé
Prostate cancer is one of the leading causes of death despite an astoundingly high survival rate for localized tumors. Though prostate specific antigen (PSA) test, performed in conjunction with digital rectal examinations, is reasonably accurate, there are major caveats requiring a thorough assessment of risks and benefits prior to conducting the test. MicroRNAs, a class of small non-coding RNAs, are stable molecules that can be detected in circulation by non-invasive methods and have gained importance in cancer prognosis and diagnosis in the recent years. Here, we investigate circulating miR-940, a miRNA known to play a role in prostate cancer progression, in both cell culture supernatants as well as patient serum and urine samples to determine the utility of miR-940 as a new molecular marker for prostate cancer detection. We found that miR-940 was significantly higher in serum from cancer patients, specifically those with clinically significant tumors (GS ≥ 7). Analysis of receiver operating characteristic curve demonstrated that miR-940 in combination with PSA had a higher area under curve value (AUC: 0.818) than the miR-940 alone (AUC: 0.75) for the diagnosis of prostate cancer. This study provides promising results suggesting the use of miR-940 for prostate cancer diagnosis.
Identifiants
pubmed: 33816263
doi: 10.3389/fonc.2021.628094
pmc: PMC8017318
doi:
Types de publication
Journal Article
Langues
eng
Pagination
628094Subventions
Organisme : NIMHD NIH HHS
ID : U54 MD006882
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA220273
Pays : United States
Organisme : NIMHD NIH HHS
ID : S21 MD012472
Pays : United States
Organisme : NIMHD NIH HHS
ID : P20 MD006882
Pays : United States
Organisme : NCI NIH HHS
ID : P20 CA233355
Pays : United States
Informations de copyright
Copyright © 2021 Rajendiran, Maji, Haddad, Lotan, Nandy, Vishwanatha and Chaudhary.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Cancer. 2019 Jun 2;10(12):2735-2744
pubmed: 31258781
Actas Urol Esp. 2014 May;38(4):217-23
pubmed: 24169211
Biosci Rep. 2019 Jun 10;39(6):
pubmed: 31085718
Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2204-2209
pubmed: 29440427
Curr Protoc Mol Biol. 2011 Jul;Chapter 15:Unit 15.10
pubmed: 21732315
Clin Chem Lab Med. 2020 Feb 25;58(3):326-339
pubmed: 31714881
Biomol Concepts. 2017 May 24;8(2):61-81
pubmed: 28448269
Sci Rep. 2019 Jun 4;9(1):8265
pubmed: 31164669
Adv Exp Med Biol. 2016;886:155-170
pubmed: 26659491
Cancer Prev Res (Phila). 2015 Feb;8(2):165-73
pubmed: 25538087
JAMA. 2015 Nov 17;314(19):2054-61
pubmed: 26575061
PLoS One. 2013 Jul 04;8(7):e67687
pubmed: 23861782
Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):5964-5971
pubmed: 30280778
Oncogene. 2019 Jul;38(28):5700-5724
pubmed: 31043708
Am J Transl Res. 2019 Aug 15;11(8):4851-4865
pubmed: 31497204
Biomed Res Int. 2016;2016:7618342
pubmed: 27807540
Br J Cancer. 2017 Apr 11;116(8):1002-1011
pubmed: 28278515
Int J Mol Sci. 2013 Aug 29;14(9):17767-80
pubmed: 23994838
Mod Pathol. 2010 Jun;23(6):814-23
pubmed: 20348879
Prostate. 2018 Feb;78(2):121-127
pubmed: 29105802
Oncotarget. 2017 Mar 21;8(12):20145-20164
pubmed: 28423620
Cancer Discov. 2016 Mar;6(3):235-46
pubmed: 26865249
Surgery. 2015 Nov;158(5):1345-51
pubmed: 26094174
Semin Oncol. 2013 Jun;40(3):259-75
pubmed: 23806492
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Int J Oncol. 2017 Mar 07;:
pubmed: 28350106
J Pathol. 2011 Sep;225(1):43-53
pubmed: 21630269
Oncol Res. 2017 Jan 2;25(1):107-114
pubmed: 28081739
Front Genet. 2013 Jun 21;4:116
pubmed: 23802013
CSH Protoc. 2007 Jul 01;2007:pdb.top17
pubmed: 21357135
Int J Mol Sci. 2014 Jan 20;15(1):1392-401
pubmed: 24447928
Nat Commun. 2018 Apr 24;9(1):1614
pubmed: 29691399
J Urol. 2013 Aug;190(2):389-98
pubmed: 23545099
JAMA. 2005 Jul 6;294(1):66-70
pubmed: 15998892
Clin Cancer Res. 2011 Jun 15;17(12):4063-70
pubmed: 21531815
Front Genet. 2014 May 27;5:149
pubmed: 24904649
Trends Cell Biol. 2012 Mar;22(3):125-32
pubmed: 22260888
J Urol. 2018 Jun;199(6):1475-1481
pubmed: 29246734
Tumour Biol. 2016 Mar;37(3):3589-97
pubmed: 26456959
Exp Mol Med. 2010 Nov 30;42(11):749-58
pubmed: 20890088
Prostate. 2019 Jun;79(9):961-968
pubmed: 30958910
Biomedicines. 2015 Nov 09;3(4):270-281
pubmed: 28536412
Med Sci Monit. 2016 Oct 12;22:3666-3672
pubmed: 27731867
Cancer Genet. 2015 Jun;208(6):289-302
pubmed: 26004033
Cell Physiol Biochem. 2015;35(3):1167-77
pubmed: 25766528
Mol Cancer. 2014 Nov 19;13:250
pubmed: 25406943
JAMA. 2018 May 8;319(18):1901-1913
pubmed: 29801017
Ann Intern Med. 2012 Jul 17;157(2):120-34
pubmed: 22801674
Onco Targets Ther. 2016 Dec 13;9:7545-7553
pubmed: 28008272
Mol Cancer Res. 2017 Jan;15(1):93-105
pubmed: 27760843
Cancer Biomark. 2018;22(3):487-493
pubmed: 29843213
Am J Cancer Res. 2019 Feb 01;9(2):250-269
pubmed: 30906627
Carcinogenesis. 2019 Apr 29;40(2):246-253
pubmed: 30452625
Actas Urol Esp. 2014 Apr;38(3):150-5
pubmed: 24099827
Annu Rev Pathol. 2014;9:287-314
pubmed: 24079833
Curr Opin Urol. 2019 Nov;29(6):593-597
pubmed: 31436568
Int J Urol. 2018 Sep;25(9):770-779
pubmed: 30129068
Bioinformatics. 2007 May 15;23(10):1289-91
pubmed: 17379693
Eur Urol. 2016 Aug;70(2):312-22
pubmed: 26806656
Cancer Lett. 2017 Oct 28;407:9-20
pubmed: 28823964